UK: PROTHERICS SEEKS BIOTECHNOLOGY DEALS
Article Abstract:
Protherics of the UK, the biotechnology company formed by the merger of Proteus and Therapeutic Antibodies, is seeking to conclude deals in the UK biotechnology sector. The strategy comes after the conclusion of a deal with US pharmaceuticals company Eli Lilly. The agreement will allow Protherics to license its molecular design technology for the development of anti-clotting drugs. It is thought that the total package may generate profits of US$ 25-40mn, although Protherics is unable to disclose any more details of the agreement.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
The miracle worker
Article Abstract:
Research indicates significant potential for slowing the deterioration in brain function associated with Alzheimer's disease, according to ReGen Therapeutics Chief Executive Mike Harvey. He believes that his company's Colostrinin product has multiple actions.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: UK: ABILITY TO PREVENT GM CONTAMINATION DOUBTED. Spread of GM crops trebles in one year. US: SPACE COLONISATION BOOSTED BY GM PLANTS
- Abstracts: UK: NETSTORE REVEALS FLOTATION DETAILS. UK: TADPOLE RAISES NEW FUNDING. UK: CAMBRIDGE SILICON CONFIRMS FLOTATION PLANS
- Abstracts: UK: CD PLAYERS TO LURE PASSENGERS ONTO TRAINS. UK: VIRGIN TRAINS PLANS EAST COAST BID. UK: EUROTUNNEL IN DEBT BUYBACK MOVE
- Abstracts: UK: CALL FOR NEW LAWS TO STOP GAZUMPING. UK: FEAR OVER HOUSE BUILDING ON FLOOD PLAINS. UK: HOUSE PRICES DROP AS SALES SLOW
- Abstracts: UK: STRONG PERFORMANCE FOR MARCONI. UK: NORTEL ANNOUNCES EXPANSION PLANS. UK: WILLIAMS LOOKS TO CONCLUDE DEMERGER